Literature DB >> 11232001

The response of molecular isoforms of growth hormone to acute exercise in trained adult males.

J D Wallace1, R C Cuneo, M Bidlingmaier, P A Lundberg, L Carlsson, C L Boguszewski, J Hay, M L Healy, R Napoli, R Dall, T Rosén, C J Strasburger.   

Abstract

Circulating GH consists of multiple molecular isoforms, all derived from the one gene in nonpregnant humans. To assess the effect of a potent stimulus to pituitary secretion on GH isoforms, we studied 17 aerobically trained males (age, 26.9 +/- 1.5 yr) in a randomized, repeat measures study of rest vs. exercise. Exercise consisted of continuous cycle ergometry at approximately 80% of predetermined maximal oxygen uptake for 20 min. Serum was assayed for total, pituitary, 22-kDa, recombinant, non-22-kDa, 20-kDa, and immunofunctional GH. All isoforms increased during, peaked at the end, and declined after exercise. At peak exercise, 22-kDa GH was the predominant isoform. After exercise, the ratios of non-22 kDa/total GH and 20-kDa GH/total GH increased and those of recombinant/pituitary GH decreased. The disappearance half-times for pituitary GH and 20-kDa GH were significantly longer than those for all other isoforms. We conclude that 1) all molecular isoforms of GH measured increased with and peaked at the end of acute exercise, with 22-kDa GH constituting the major isoform in serum during exercise; and 2) the proportion of non-22-kDa isoforms increased after exercise due in part to slower disappearance rates of 20-kDa and perhaps other non-22-kDa GH isoforms. It remains to be determined whether the various biological actions of different GH isoforms impact on postexercise homeostasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11232001     DOI: 10.1210/jcem.86.1.7129

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Molecular heterogeneity of human GH: from basic research to clinical implications.

Authors:  C L Boguszewski
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

3.  Exercise modulation of growth hormone isoforms: current knowledge and future directions for the exercise endocrinologist.

Authors:  B C Nindl
Journal:  Br J Sports Med       Date:  2007-01-19       Impact factor: 13.800

Review 4.  Human growth hormone doping in sport.

Authors:  M Saugy; N Robinson; C Saudan; N Baume; L Avois; P Mangin
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

5.  Endocrine response to acute resistance exercise in obese versus lean physically active men.

Authors:  Daniela A Rubin; Hoang N Pham; Eric S Adams; Andrew R Tutor; Anthony C Hackney; Jared W Coburn; Daniel A Judelson
Journal:  Eur J Appl Physiol       Date:  2015-01-30       Impact factor: 3.078

Review 6.  Hormones as doping in sports.

Authors:  Leonidas H Duntas; Vera Popovic
Journal:  Endocrine       Date:  2012-09-19       Impact factor: 3.633

Review 7.  Hormonal responses and adaptations to resistance exercise and training.

Authors:  William J Kraemer; Nicholas A Ratamess
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

Review 8.  Growth hormone release during acute and chronic aerobic and resistance exercise: recent findings.

Authors:  Laurie Wideman; Judy Y Weltman; Mark L Hartman; Johannes D Veldhuis; Arthur Weltman
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

9.  Repetitive stimulation of the pituitary with growth-hormone-releasing hormone alters the proportion of 22 and 20 kilodalton human-growth hormone released.

Authors:  Emma A Webb; P Jane Pringle; Iain C A F Robinson; Peter C Hindmarsh
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-09

10.  Growth hormone isoforms release in response to physiological and pharmacological stimuli.

Authors:  S Pagani; M Cappa; C Meazza; G Ubertini; P Travaglino; E Bozzola; M Bozzola
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.